Welcome to MedArena!

Your trusted destination for CME, CPD & Medical Education across the Middle East.

Information

  • Address:MedArena Corporation
  • Call Us:1 (800) 828-2059
  • Email:support [at] medarenaevents.com
Dr. David Bearss

Achievements

—Co-founded eight biotechnology companies.
—Advanced more than a dozen compounds into clinical development.
—Received the Utah Governor's Medal of Science.

Dr. David Bearss

CEO

Halia Therapeutics

About

Dr. David Bearss is a scientist, biotechnology entrepreneur and drug-development executive with more than two decades of experience in pharmaceutical research. He currently serves as CEO of Halia Therapeutics, where he leads development of therapies targeting chronic inflammation, neurodegeneration and related diseases. He has co-founded multiple biotechnology companies and has advanced numerous compounds from discovery through clinical development. Earlier in his career, he held academic positions at the University of Utah and Brigham Young University and worked at Tolero Pharmaceuticals and other biotechnology companies. His expertise includes structure-based drug discovery, cancer biology and translational therapeutics.

Dr. David J. Bearss is an American scientist, biotechnology entrepreneur, and pharmaceutical executive with extensive experience in drug discovery, cancer research, and pharmaceutical development. He is known for founding biotechnology companies, advancing experimental medicines into clinical development, and translating scientific discoveries into potential treatments for serious diseases.

Dr. Bearss earned his bachelor's degree from Brigham Young University and his Ph.D. in Cell Biology from the University of Texas Health Science Center at San Antonio. He subsequently completed postdoctoral training in oncology and drug development, developing expertise in cancer biology, molecular pharmacology, and translational research.

In 2003, Dr. Bearss founded Montigen Pharmaceuticals, a biotechnology company focused on drug discovery and development. The company was acquired by SuperGen Inc. in 2006. Following the acquisition, he held scientific leadership positions, including Chief Scientific Officer, where he contributed to early-stage pharmaceutical research and the advancement of potential drug candidates.

Dr. Bearss also pursued an academic career at the University of Utah and Brigham Young University. At the University of Utah's Huntsman Cancer Institute, he helped establish the Center for Investigational Therapeutics and served as its founding co-director. His academic work focused on oncology, therapeutic development, and collaboration between laboratory researchers and clinical investigators.

In 2011, he co-founded Tolero Pharmaceuticals and became its Chief Executive Officer. Under his leadership, the company developed experimental treatments for cancer and other serious diseases. Tolero was acquired by Sumitomo Dainippon Pharma in 2017 in a transaction reported to have a potential value of approximately US$780 million, including milestone payments. The acquisition represented a significant milestone in his biotechnology career.

Dr. Bearss later co-founded Halia Therapeutics, a biotechnology company focused on developing treatments for chronic inflammation, neurodegenerative diseases, and other serious medical conditions. He joined the company as Chief Scientific Officer in January 2021 and became President and Chief Executive Officer in March 2022.

At Halia Therapeutics, his work has focused on translating discoveries in inflammation biology and genetic resilience into potential therapies. The company's research programs have included investigations into myelodysplastic syndromes, Alzheimer's disease, and inflammatory disorders.

Throughout his career, Dr. Bearss has been involved in founding or co-founding multiple biotechnology companies and advancing experimental compounds into clinical development. His professional achievements have been recognized within Utah's biotechnology industry, including recognition associated with the Utah Governor's Medal of Science and BIO Utah's Entrepreneur of the Year award.

His career combines scientific research, pharmaceutical development, academic leadership, and biotechnology entrepreneurship, with a continuing focus on discovering and developing potential treatments for cancer and other serious diseases.

Full Achievement Timeline

Early Career — Academic and Scientific Training

  • Earned a bachelor's degree from Brigham Young University.
  • Completed a Ph.D. in Cell Biology at the University of Texas Health Science Center at San Antonio.
  • Undertook postdoctoral training in oncology and drug development.
  • Developed expertise in cancer biology, molecular pharmacology, and therapeutic discovery.

2003 — Founded Montigen Pharmaceuticals

  • Established a biotechnology company focused on drug discovery and development.
  • Led research initiatives aimed at identifying and advancing potential therapeutic compounds.
  • Began building his reputation as a scientist and biotechnology entrepreneur.

2006 — Montigen Pharmaceuticals Acquired

  • Montigen Pharmaceuticals was acquired by SuperGen Inc.
  • Continued working in pharmaceutical research and scientific leadership.
  • Expanded his experience in drug development and biotechnology operations.

2000s — Scientific Leadership at SuperGen

  • Held senior scientific responsibilities, including the role of Chief Scientific Officer.
  • Contributed to early-stage drug discovery and development.
  • Supported the advancement of potential medicines toward clinical evaluation.

2000s–2010s — Academic Leadership

  • Served as an associate professor at the University of Utah and Brigham Young University.
  • Helped establish the Center for Investigational Therapeutics at the Huntsman Cancer Institute.
  • Promoted collaboration between laboratory research and clinical drug development.

2011 — Co-Founded Tolero Pharmaceuticals

  • Co-founded Tolero Pharmaceuticals and became its Chief Executive Officer.
  • Led company strategy, research priorities, fundraising, and pharmaceutical development.
  • Oversaw programs focused on experimental treatments for cancer and other serious diseases.

2011–2017 — Advanced Pharmaceutical Development

  • Guided drug candidates through preclinical research and clinical development.
  • Supported research into hematologic malignancies and other diseases.
  • Built relationships with investors, pharmaceutical organizations, and research institutions.

2017 — Tolero Pharmaceuticals Acquisition

  • Led Tolero through its acquisition by Sumitomo Dainippon Pharma.
  • The transaction was reported at approximately US$780 million in potential value, including contingent milestone payments.
  • Reached a major milestone in biotechnology entrepreneurship and pharmaceutical development.

January 2021 — Joined Halia Therapeutics

  • Became Chief Scientific Officer.
  • Focused on research involving chronic inflammation, molecular pathways, and disease biology.
  • Helped shape the company's scientific strategy and therapeutic development programs.

March 2022 — Became President and CEO of Halia Therapeutics

  • Assumed responsibility for corporate strategy, research priorities, and business development.
  • Led efforts to translate discoveries in inflammation biology into potential treatments.
  • Expanded the company's focus on experimental therapies for serious diseases.

2022–2024 — Expanded Research Programs

  • Supported research into chronic inflammation, neurodegeneration, and hematologic disorders.
  • Advanced investigations into biological pathways that may contribute to disease development.
  • Promoted translational research aimed at moving laboratory discoveries toward clinical applications.

2023 — Biotechnology Industry Recognition

  • Continued to be recognized for his contributions to biotechnology entrepreneurship and drug development.
  • Professional profiles highlighted his experience founding biotechnology companies and advancing drug candidates.
  • Maintained an active role in Utah's life-sciences community.

2025 — Continued Drug Discovery Leadership

  • Continued leading biotechnology research and development initiatives.
  • Supported programs investigating potential therapies for inflammatory diseases, cancer, and neurodegenerative conditions.
  • Continued applying his experience in scientific strategy and pharmaceutical development.

2026 — Continued Biotechnology Entrepreneurship

  • Continues to be associated with Halia Therapeutics as a biotechnology executive.
  • Maintains a focus on drug discovery, inflammation biology, genetic resilience, and experimental therapeutics.
  • Continues contributing to the biotechnology sector through scientific leadership and entrepreneurship.

Major Achievements and Awards

1. Founder of Montigen Pharmaceuticals — Established a biotechnology company focused on drug discovery and development.

2. Co-Founder and CEO of Tolero Pharmaceuticals — Built and led a pharmaceutical company developing experimental treatments for cancer and other serious diseases.

3. Tolero Pharmaceuticals Acquisition in 2017 — Led the company through its acquisition by Sumitomo Dainippon Pharma in a transaction with a reported potential value of approximately US$780 million, including milestone payments.

4. Co-Founder of Multiple Biotechnology Companies — Has founded or co-founded eight biotechnology companies, according to professional biographies.

5. Advancement of Drug Candidates — Has contributed to moving numerous experimental compounds from laboratory discovery into clinical development.

6. Utah Governor's Medal of Science — Listed in professional biographies among his recognitions for scientific and entrepreneurial contributions.

7. BIO Utah Entrepreneur of the Year — Recognized for contributions to biotechnology entrepreneurship.

8. Extensive Patent Portfolio — Earlier professional profiles credited him with more than 75 patents.

9. Founding Co-Director of the Center for Investigational Therapeutics — Helped establish a center dedicated to accelerating translational research and therapeutic development.

10. Leadership at Halia Therapeutics — Leads research and development programs involving chronic inflammation, neurodegeneration, and potential treatments for serious diseases.

Institutional Affiliations

Halia Therapeutics

Position: Co-Founder, President, and Chief Executive Officer.

Focus: Chronic inflammation, neurodegeneration, genetic resilience, and drug development.

Tolero Pharmaceuticals

Position: Co-Founder and former Chief Executive Officer.

Focus: Oncology, pharmaceutical development, and experimental therapeutics.

Montigen Pharmaceuticals

Position: Founder and former scientific leader.

Focus: Drug discovery and early-stage pharmaceutical research.

SuperGen Inc.

Position: Former scientific leader and Chief Scientific Officer.

Focus: Early-stage drug discovery and pharmaceutical development.

Huntsman Cancer Institute, University of Utah

Position: Founding Co-Director of the Center for Investigational Therapeutics and former Associate Professor of Oncological Sciences.

Focus: Translational oncology and experimental cancer treatments.

Brigham Young University

Position: Former Associate Professor of Physiology and Developmental Biology.

Focus: Biomedical research, teaching, and scientific education.

Events & Activities

Abu Dhabi Future Health Summit 2026
Oct 20, 2026
In-Person

Abu Dhabi Future Health Summit 2026

dmg events

  • CME Credits
  • Abu Dhabi National Exhibition Centre (ADNEC), Abu Dhabi
Oct 20, 2026
In-Person

Abu Dhabi Future Health Summit 2026

Free

The Abu Dhabi Future Health Summit 2026 is a premier global platform uniting researchers, policymakers, and healthcare specialists to drive transformative health innovation and accelerate collaboration for longer, healthier lives.

dmg events

  • 3 Days
  • Abu Dhabi National Exhibition Centre (ADNEC), Abu Dhabi
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
Dr. David Bearss — CEO | MedArena